A Intra-individual Comparison to Investigate the Efficacy and the Safety of LAS41004 Formulation in Mild to Moderate Psoriasis

NCT02180464 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: LAS41004
DRUG: control

Sponsor

Almirall, S.A.